This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Vokes, Everett E.
Item Type | Name |
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
Concept
|
Vascular Endothelial Growth Factor A
|
Academic Article
|
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
Academic Article
|
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
|
Academic Article
|
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
|
Academic Article
|
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
|
Academic Article
|
Role of protein kinase C ß and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
|
Academic Article
|
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
|
Academic Article
|
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
|
Academic Article
|
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
|
Academic Article
|
Angiogenesis inhibition in the treatment of lung cancer.
|
Academic Article
|
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
|
Academic Article
|
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
|
Academic Article
|
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
|
Academic Article
|
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
|
- Vascular Endothelial Growth Factor C